Source: Eur Respir Monogr 2022; 96: 328-336



Rating:

Share or cite this content

Citations should be made in the following way:
Canay Caliskan, Antje Prasse. Treating sarcoidosis and potential new drugs. Eur Respir Monogr 2022; 96: 328-336

Member's Comments

No comment yet.

Related content which might interest you: Atypical mycobacteriosis : new drugs, new strategies Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease Year: 2004 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 An evidence-based and step-wise approach to treat pulmonary sarcoidosis with old and new drugs Source: International Congress 2019 – State of the art session: Interstitial lung diseases Year: 2019 The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Combining corticosteroids and NK1R antagonists: A new drugs combination to treat allergic diseases Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 New drugs for severe asthma – what should we target and how? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020 Year: 2020 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007